Pfizer Inc announced on Thursday that it has signed a $5.29 billion deal with the US government to deliver 10 million courses of its COVID-19 oral antiviral drug starting this year.
The oral drug could be a promising new weapon in the fight against the pandemic, as it can be used as an early at-home treatment to help prevent COVID-19 hospitalizations and deaths.
Pfizer filed for US approval of Paxlovid on Tuesday, stating that it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.
The company announced earlier…
